Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.57 |
| ▸ | MTOR | P42345 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11670110 | 0.83 | ADRB2 (0.52) | ADRB3ADRB2ADRB1 | |
| SCHEMBL4427576 | 0.82 | ADRB3 (0.64) | ADRB3MAPTADRB2KDM4ETDP1 | |
| SCHEMBL11028018 | 0.81 | CYP1A2 (0.57) | ADRB3MAPTADRB2KDM4ETDP1 | |
| SCHEMBL11823870 | 0.81 | ADRB3 (0.63) | ADRB3MAPTADRB2KDM4ETDP1 | |
| SCHEMBL11816799 | 0.81 | ADRB3 (0.63) | ADRB3MAPTADRB2KDM4ETDP1 | |
| Hydrochloric Acid SCHEMBL11431747 | 0.81 | ADRB2 (0.56) | ADRB3MAPTADRB2KDM4ETDP1 | |
| Hydrochloric Acid SCHEMBL11823842 | 0.80 | TSHR (0.62) | ADRB3MAPTADRB2KDM4ETDP1 | |
| SCHEMBL11878468 | 0.77 | MAPT (0.71) | ADRB3MAPTADRB2KDM4ETDP1 | |
| SCHEMBL278660 | 0.76 | ADRB3 (0.66) | ADRB3MAPTADRB2KDM4ETDP1 | |
| SCHEMBL8009724 | 0.75 | CYP1A2 (0.75) | MAPTCYP1A2MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285900-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A BETA-AGONIST BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS, LLC | 2009-11-19 | — | — | US | disclosed |
| EP-1651168-A4 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A BETA-AGONIST BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS LLC (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-1651168-A2 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A BETA-AGONIST BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Epigenesis Pharmaceuticals LLC (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050113318-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACUETICALS, LLC | 2005-05-26 | — | — | US | disclosed |
| WO-2005011603-A2 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A BETA-AGONIST BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS LLC (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20050026884-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACEUTICALS LLC | 2005-02-03 | — | — | US | disclosed |
| US-3994974-A | BRONCHODILATORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113318-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease | HSD3B2, ADRB2, HSD11B2 | ADRB3 14/4885MAPT 4261/4885ADRB2 2/4885 |
| US-20050026884-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease | HSD3B2, HSD3B1, ADRB2 | ADRB3 14/4885MAPT 4193/4885ADRB2 3/4885 |
| US-20090285900-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A BETA-AGONIST BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | HSD3B2, ADRB2, HSD11B2 | ADRB3 14/4885MAPT 4261/4885ADRB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.